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A B S T R A C T
Background: Infections with parvovirus B19 (B19V) have been associated with a wide range of disease mani-
festations of which erythema infectiosum (ﬁfth disease) in children is most common. Clinical signs following
infection of children with B19V can be similar to measles and rubella. Laboratory detection of B19V infections is
based on detection of B19V-speciﬁc IgM antibodies by enzyme immunoassay (IgM-EIA) and/or B19V DNA by
quantitative PCR (qPCR) on blood samples. The need for invasive sampling can be a barrier for public health
diagnostics.
Objectives: To evaluate the use of a dual target B19V-qPCR directed against the NS1 and VP2 of B19V on oral
ﬂuid samples as a non-invasive alternative for laboratory diagnosis of B19V infections in children below 12 years
of age with exanthema.
Study design: Oral ﬂuid and serum samples were collected from 116 children with exanthema. All serum samples
were tested by IgM-EIA/IgG-EIA, while all oral ﬂuid and 56 serum samples were tested by B19V-qPCR.
Results: B19V-speciﬁc IgM antibodies were detected in 25 of 116 children in the study. B19V DNA was detected
in oral ﬂuid in 17 of the 25 children who were IgM positive, as well as two children who were IgM-equivocal or
negative. The child with the equivocal IgM had a high quantity of B19V DNA in oral ﬂuid (7 log IU/ml),
compatible with an acute B19V infection. The IgM-negative child was IgG-positive and 4 log IU/ml B19V DNA
was detected in the oral ﬂuid sample, suggesting an acute infection and a falsely negative IgM. Sample size
calculations indicated that oral ﬂuid samples for qPCR should be collected from 2 to 3 children during outbreaks
of exanthema to achieve similar sensitivity as IgM-EIA for one child (≥0.9) to conﬁrm or exclude B19V.
Conclusions: Results indicate that oral ﬂuid samples are a suitable public health alternative for detection of B19V
infections, potentially lowering the barriers for sampling.
1. Background
Infection with parvovirus B19 (B19V) causes erythema infectiosum
in children (so called “slapped cheek disease” or” ﬁfth disease”) and
arthropathies in adults, although 25–50% of infections are subclinical
[1–3]. In pregnant women, transplacental transmission of the virus to
the fetus can result in hydrops fetalis, fetal or congenital anemia,
abortion, or stillbirth [1,4,5]. Furthermore, various complications have
been described following infection with B19 V [1].
Diagnosis of B19V infections in children with exanthema is of in-
terest since B19V infections in children pose a risk for transmission to
pregnant mothers [5]. In addition, B19V is one of the viruses that can
cause exanthema in children, similar to rubella virus and measles virus,
and inclusion of B19V detection in a viral panel for diagnosis of ex-
anthemas would result in an increase in the proportion of cases with a
positive diagnosis [6–8].
Laboratory diagnosis of acute infections with B19V is currently
based on serological assays, such as enzyme immunoassays (EIA) to
detect B19V-speciﬁc IgM and IgG antibodies, and molecular assays, to
detect circulating B19V DNA in blood samples. Various studies have
demonstrated that a combination of these two provided the most sen-
sitive diagnosis of B19V infections [9–13]. In most cases, a positive IgM
response in combination with clinical signs of B19V infection will
provide an accurate diagnosis of a case of ﬁfth disease. In some cases,
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collection of the blood sample might have been too early to detect a
positive B19V-IgM response, while B19V DNA can already be detected
in a blood sample. However, B19V DNA can remain present in the blood
stream for at least several months after infection. Therefore, a clear link
between the onset of clinical disease (exanthema) is important for the
interpretation of the laboratory results [14,15].
However, often no samples of suspected cases are collected from
children with exanthema. The availability of a non-invasive sampling
method might increase the willingness of children and their parents to
provide a sample for diagnostics. Collection of a ﬁngerprick blood
sample can be considered a ﬁrst alternative to collect serum samples for
diagnostics [9]. However, this is still perceived as slightly invasive and
requires medical assistance.
Oral ﬂuid sampling might be a suitable, non-invasive, easy-to-use
alternative for diagnosis of acute B19V infections. Quantitative reverse
transcriptase PCR (RT-qPCR) is already routinely performed on oral
ﬂuid for measles and rubella virus and detection of B19V DNA by qPCR
on oral ﬂuid samples could be an integral part of laboratory diagnostics
currently performed for diagnosis of outbreaks of exanthema [16].
2. Objectives
The objective of this study was to evaluate the use of qPCR on oral
ﬂuid samples for the diagnosis of B19V infections in children with non-
vesicular exanthema in a direct comparison with IgM antibody detec-
tion in serum. The obtained sensitivity (and speciﬁcity) of the B19V-
qPCR was used to calculate the number of children that needs to be
sampled for detection of B19V as the causative agent of an outbreak of
exanthema for public health purposes.
3. Study design
3.1. Selection of clinical cases
Samples were collected from children attending day care and pri-
mary school (maximum 12 years of age) within maximum 14 days after
development of a maculopapular rash (exanthema). Collection of
samples was performed within the context of a Dutch surveillance
protocol for laboratory diagnosis of infections with measles, B19V or
rubellavirus in children with exanthema. To prevent missing children
with especially rubellavirus infection, the inclusion criterion for sub-
mitting samples for laboratory diagnostics was limited to the presence
of an exanthema only. Samples were used that were collected from
children during two periods, between December 2003 and July 2005
(group 1) and between March 2010 and January 2018 (group 2). Large
outbreaks of rubella and measles virus occurred in the Netherlands
from September 2004 until July 2005 [17] and from May 2013 until
March 2014 respectively [18]. Informed consent to obtain clinical
specimens for laboratory diagnosis and additional test validations was
obtained from the parents.
3.2. Sample and data collection
From children with exanthema, an oral ﬂuid and a blood sample
were collected. Oral ﬂuid samples were collected using an oral ﬂuid
collection system containing a sponge (Oracol, Malvern Medical
Developments). Blood samples from the ﬁrst group were collected on
dried blood spot cards (Protein Saver™ 903™, Whatman), while blood
samples from the second group were collected in Microtainer tubes
(Becton Dickinson).
Samples were submitted to the diagnostic laboratory of the
Netherlands National Institute for Public Health and the Environment
(RIVM). Upon arrival, samples were stored at +4 ºC until further pro-
cessing for laboratory diagnosis of measles and rubella virus infection
by RT-qPCR and B19V infection by IgM-EIA and IgG-EIA. Remaining
sample material was stored at -70ºC until use for detection of B19V
DNA by qPCR.
From each child, the date of onset of prodromal symptoms and/or
the date of onset of exanthema, the date of sample collection and date
of birth were registered.
3.3. Molecular diagnostics
Nucleic acids were extracted from oral ﬂuid and serum samples
using the MagNA Pure96 (Roche) according to the protocol of the
manufacturer. Oral ﬂuid samples were subsequently tested for the
presence of measles virus RNA and rubellavirus RNA by RT-qPCR es-
sentially as described previously using TaqMan Fast virus One-step
Master Mix on a Roche LC480 platform [16].
In addition, oral ﬂuid samples and serum samples stored in micro-
tainer tubes (group 2) were tested for the presence of B19V DNA using a
multiplex dual-target qPCR with primers and probes targeting the
partial NS1 and VP2 genes as described previously [19]. B19V qPCR on
serum and oral ﬂuid were performed using TaqMan Fast virus One-step
Master Mix on a Roche LC480 platform. Oral ﬂuid and serum samples
were considered positive when a clear positive signal was detected with
either or both the NS1 and VP2 qPCR. Samples with a discordant result
between the two qPCRs and a relatively high qPCR Ct-value, were re-
tested.
3.4. Serological diagnostics
Fingerprick blood samples from group 1 were collected on dried
blood spot cards and were harvested according to a standard protocol.
Fingerprick blood samples from group 2 were collected in Microtainer
tubes and tubes containing clotted blood were centrifuged and serum
was harvested. The obtained serum was subsequently tested for the
presence of B19V-speciﬁc IgG and IgM antibodies using a B19V-speciﬁc
IgG and IgM EIA (Biotrin International) according to the instructions of
the manufacturer.
3.5. Statistical analysis
The correlation between the obtained qPCR targeting the partial
NS1 and VP2 (IU/ml) genes and the correlation between the obtained
qPCR results and the interval between collection date and date of onset
of exanthema were calculated using Pearson correlation coeﬃcient (r).
Statistical analysis of proportions of qPCRposIgM-EIApos/ IgM-EIApos
samples of both groups was performed using Fisher’s exact test in R
version 3.4.3 [20]. Sensitivity and speciﬁcity of the qPCR were calcu-
lated using IgM-EIA as the reference standard.
3.6. Evaluation of sample size collection
The calculated sensitivity of the qPCR was used to evaluate how the
qPCR could be implemented for diagnostics to detect B19V as the
causative agent during an outbreak of exanthema among children in a
public health setting. If B19V can be excluded in case an outbreak is
caused by another pathogen is indicated by the speciﬁcity of the qPCR.
The chance of detection of a B19V positive sample (Pdetect X > 0)
during an outbreak of B19V (e.g. at a day care centre) was calculated
for both the IgM-EIA and qPCR assuming that samples collected during
an outbreak of exanthema at the same time and at the same location
will involve only a single pathogen. Thus, the prevalence of B19V
during an outbreak of this virus was estimated to be 90–100% in the
collected samples if samples are collected from children with ex-
anthema only. A somewhat lower prevalence of B19V in the samples
might be expected if clinical signs are not very clear in all children from
whom samples were collected. Therefore, Pdetect X > 0 was calculated
for sample prevalences of 80, 90 and 100% and a sample size ranging
from one to four samples using the following formula in R version 3.4.3
[20]:
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Pdetect = 1-(1-prevalence)n (for IgM-EIA)
Pdetect = 1-(1-sensitivity*prevalence)n (for qPCR)
4. Results
4.1. Study population
In total 116 cases of children with exanthema were included in this
study. The ﬁrst group consisted of 60 children (mean age 5.2 years) and
the second group of 56 children (mean age 4.1 years).
4.2. Detection of measles and rubella virus by RT-qPCR
Infection with rubellavirus was conﬁrmed in 21 children by RT-
qPCR of the ﬁrst group, while no measles or rubellavirus was detected
by RT-qPCR in samples collected from the other children of both
groups.
4.3. Detection of B19V infection(s) by serology
B19V-speciﬁc IgM antibodies were detected in 25 of 116 in-
vestigated children, while two samples were considered equivocal
(Table 1). The youngest child with a positive B19V-speciﬁc IgM re-
sponse was 2.8 years of age. B19V-speciﬁc IgG antibodies were detected
in 49 of 114 tested children and results from 7 samples were considered
equivocal (Table 1). From two children, serum could not be tested for
the presence of B19V-speciﬁc IgG antibodies since the amount of
available serum from these children was very limited. In all samples
that tested positive for the presence of B19V-speciﬁc IgM antibodies,
also B19V-speciﬁc IgG antibodies were detected (Table 1).
4.4. Detection of B19V infection(s) by qPCR
B19V was detected in 19 of 116 oral ﬂuid samples by qPCR com-
prising the children of both group 1 and group 2 (Table 2). Within
group 2, B19V DNA was detected in 18 of 56 tested serum samples. For
11 of these children (61%), B19V DNA was also detected in oral ﬂuid
(Tables 2, 3 and S1, Fig. 1).
In 17 out of 18 qPCR positive serum samples, B19V DNA was de-
tected by both qPCRs directed against NS1 and VP2, while in one case
B19V DNA was detected in serum by qPCR directed against VP2 only. In
total 16 out of 19 positive oral ﬂuid samples tested positive for the
presence of B19V DNA by both qPCRs directed against NS1 and VP2,
while in three cases B19V DNA was detected by qPCR targeting either
NS1 or VP2 (data not shown). The Pearson correlation coeﬃcient r
between the two qPCRs for oral ﬂuid samples was 0.93 (Fig. S1).
The mean quantity of B19V DNA detected in positive oral ﬂuid
samples was 3.9 10log IU/ml (S.D. 1.5 10log IU/ml) and 3.9 10log IU/ml
(S.D. 1.4 10log IU/ml) for the NS1-qPCR and VP2-qPCR respectively.
The mean quantity of B19V DNA detected in positive serum samples
was 2.8 10log IU/ml (S.D. 0.8 10log IU/ml) and 3.5 10log IU/ml (S.D. 1.2
10log IU/ml) respectively. There was no linear relationship between the
quantity of B19V DNA and the number of days between collection and
onset of exanthema, in both serum and oral ﬂuid samples (r-values
ranging from 0.005-0.011) (Fig. S2).
4.5. Comparison of detection of B19V infections by IgM-EIA and qPCR
In six of the eight children (75%) with B19V-speciﬁc IgM antibodies
also B19V DNA was detected by qPCR in oral ﬂuid in the ﬁrst group and
in 11 of the 17 children of the second group (65%). Since results of both
groups were similar (Fisher’s exact test p= 0.67), results of both groups
were combined (Table 3; sensitivity 68%). The qPCR on oral ﬂuid was
negative for 89 out of 91 IgM-EIA negative/equivocal children (speci-
ﬁcity 98%). No children that tested positive for rubellavirus infection
by RT-qPCR tested positive for B19V infection by IgM-EIA and qPCR.
B19V DNA was detected in 18 serum samples, 17 of these serum
samples tested also positive by IgM-EIA (sensitivity 100% of qPCR on
serum) (Table 3, Fig. 2). One child had relatively low Ct-values (mean
Ct-value 0.85 10log IU/ml) without a positive IgM-EIA and IgG-EIA test
result.
Table 1
Combination of laboratory results of IgM-EIA and IgG-EIA.
Test Result IgM-EIA
Positive Equivocal Negative Total
IgG-EIA
Group 1
Positive 8 0 20 28
Equivocal 0 0 3 3
Negative 0 1 27 28
Total 8 1 50 59
IgG-EIA
Group 2
Positive 17 0 5 22
Equivocal 0 0 4 4
Negative 0 1 28 29
Total 17 1 37 55
Table 2
Overview of all laboratory results for all children in this study subdivided by
their laboratory results.
Group IgM IgG qPCR serum qPCR oral ﬂuid Number of children
1 + + n.d. + 6
+ + n.d. – 2
equiv. – n.d. + 1
– + n.d. + 1
– + n.d. – 19
– equiv. n.d. – 3
– n.d. n.d. – 1
– – n.d. – 27
Total 60
2 + + + + 11
+ + + – 6
equiv. – – – 1
– + – – 4
– – + – 1
– equiv. – – 4
– n.d. – – 1
– – – – 28
Total 56
n.d.: no data.
equiv.: equivocal EIA results.
Table 3
Combination of results of IgM-EIA and qPCR of both groups.
qPCR sample Laboratory results Number of children
IgM qPCR result
Oral ﬂuid Positive Positive 17
Positive Negative 8
Equivocal Positive 1
Equivocal Negative 1
Negative Positive 1
Negative Negative 87
Total 116
Serum Positive Positive 17
Positive Negative 0
Equivocal Positive 0
Equivocal Negative 1
Negative Positive 1
Negative Negative 37
Total 56
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4.6. Estimation of sample size collection during an outbreak of B19V
Pdetect correlated with the prevalence and was higher for IgM-EIA
than for qPCR. With a prevalence of 0.8 at least 3 children needs to be
sampled for qPCR and at least 2 children needs to be sampled with IgM-
EIA to detect a B19V infection with≥90%, while with a prevalence of 1
only 2 and 1 children should be sampled respectively (Fig. 3).
5. Discussion
In the present study, the use of oral ﬂuid samples for molecular
detection of B19V in children with exanthema was evaluated as a non-
invasive alternative for ﬁngerprick blood sampling. Comparison of re-
sults from B19V-qPCR on oral ﬂuid with B19V-IgM-EIA on serum re-
vealed that detection of B19V DNA in oral ﬂuid is possible although
with lower sensitivity (68%) compared to the IgM-EIA. Only children
were included from which samples were collected within 14 days of
onset of exanthema. Therefore we anticipated that a case with
exanthema and a positive B19V-IgM-EIA result was a child with a re-
cent B19V infection (ﬁfth disease). In addition, all IgM positive cases of
the second group could be conﬁrmed by detection of B19V DNA in
serum in our study.
Both sensitivity and speciﬁcity are likely somewhat underestimated
as two children with negative/equivocal B19V-IgM-EIA results tested
clearly positive in the qPCR on oral ﬂuid. Samples from one child were
collected one day after the onset of exanthema. A high copy number of
B19V DNA was detected in oral ﬂuid (7.0 and 7.5 log IU/ml in the NS1
and VP2 qPCR respectively), while B19V-IgM-EIA results were equi-
vocal. It was presumed that samples from this child were collected too
early for adequate antibody detection. Samples from the other child
were collected four days after the onset of exanthema and B19V-IgG
antibodies were detected in serum. Since B19V DNA was clearly de-
tected in oral ﬂuid by both B19V-qPCRs (4.5 and 4.3 log IU/ml in the
NS1 and VP2 qPCR respectively), it was presumed that the results of the
B19V-IgM-EIA were false negative and that this was a child with an
ongoing infection or possibly reactivation. Therefore, both children
Fig. 1. Associations between quantitative B19V-qPCR results in serum and oral ﬂuid. Oral ﬂuid (OF) samples from all children and serum samples from children of
group 2 were tested both by NS1 (A) and VP2 (B) B19V-qPCR. Collected qPCR results from individual cases are indicated in IU/ml.
Fig. 2. Associations between quantitative
B19V-qPCR and B19V-IgM/IgG-EIA results.
Oral ﬂuidsamples from all children (A, B) and
serum from samples of group 2 (C, D) were
tested for the presence of B19V DNA by a NS1
(A, C) and VP2 speciﬁc qPCR (B, D). Data from
obtained qPCR results were presented with
data from individual B19V-IgM/IgG-EIA (ne-
gative [−], positive [+], or equivocal [e]).
The light grey areas indicate the values where
qPCR results were considered negative. Data
from all individual children are indicated by
triangles. Laboratory results of children with a
discrepancy between the NS1 and VP2 qPCR
are indicated with diﬀerent symbols.
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were considered as cases of ﬁfth disease. On the other hand, in serum
from one child a relatively low amount of B19V DNA was detected in
the absence of B19V-speciﬁc IgM and IgG antibodies and it was pre-
sumed that this was a false positive B19V-qPCR result [21].
The results of our study conﬁrm the results of previous studies,
which demonstrated that the most sensitive diagnosis of ﬁfth disease is
based on both qPCR and IgM-EIA [9–13,21]. When the two cases with a
equivocal/negative IgM and clear positive qPCR result are indeed in-
cluded as B19V cases to calculate a composite reference standard based
on the combined results of qPCR on oral ﬂuid and IgM-EIA, the sensi-
tivity of the qPCR on oral ﬂuid would increase to 70% [22].
Of interest, oral ﬂuid has been used previously for detection of
B19V-speciﬁc IgM and IgG, but the sensitivity was lower compared to
serum and also slightly lower (60%) than the qPCR on oral ﬂuid as used
in this study [23]. In addition, oral ﬂuid was chosen instead of a nasal
or pharyngeal swab for detection of B19V DNA since it was easiest to
obtain and already common practice for detection of measles and ru-
bellavirus by RT-qPCR.
The relative low sensitivity of the qPCR on oral ﬂuid compared to
the IgM-EIA could be explained by the limited or short period of ex-
cretion of B19V via the respiratory tract, as shown previously for B19V
infected adults [24,25]. Therefore, we limited the analysis to samples
that were collected within 14 days of onset of exanthema.
The clinical criterion for collection of samples was the presence of
exanthema only. Although infections with rubella virus and B19V could
explain the exanthema in a proportion of the children, the cause of
exanthema in the majority of the children remained unclear and could
be of non-infectious etiology. However, an infectious cause was sus-
pected in case more children presented exanthema at the same time
[26,27].
Among the children that tested positive by B19V-qPCR in oral ﬂuid,
three diﬀerent epidemiological clusters could be deﬁned based on
available metadata (date of sample collection, place, and school). Two
clusters consisted of two children each. In these clusters, results of
B19V-IgM-EIA and B19V-qPCR on serum were positive in both children,
while B19V DNA could be detected in one oral ﬂuid sample of each
cluster. The third cluster consisted of four children. Results of B19V-
IgM-EIA and B19V-qPCR on serum were also positive in all four chil-
dren, while B19V DNA could be detected in oral ﬂuid in three children.
In one of these children B19V DNA could be detected by qPCR against
only one target (NS1).
In conclusion, results of the present study indicate that molecular
detection of B19V on oral ﬂuid is a suitable non-invasive alternative for
public health diagnostics to detect or exclude B19V as the causative
agent of outbreaks of exanthema among children at a day-care-centre or
school.
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